Choose your preferred payment option
A separate real-world cohort study published earlier in 2026 found that semaglutide cut major cardiovascular events by 29% compared with tirzepatide in 21,250 patients without diabetes, though that study was funded by semaglutide's own manufacturer.2 A new study from Brigham and Women's Hospital asks a narrower, related question: among people who have both type 2 diabetes and a specific type of heart failure, does either drug lower the risk of hospitalization or death more than the other
Surprisingly, it wasn't the high saturated fat or cholesterol content in the meat, but a different compound called L-carnitine
Key criteria from UHC's official policy (P 1114-18): [3] BMI 30 , or 27 with a comorbidity (a weight-related health condition like diabetes, high blood pressure, sleep apnea, or high cholesterol) Age 12+ (adults or adolescents with BMI 95th percentile) Lifestyle modifications documented (diet, exercise, behavioral support) Initial approval: 5 months